Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 97 positions · Total reported value $2.81B · Top-10 concentration 53.0% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Soleus Capital Management, L.P. disclosed 97 equity positions with a combined reported value of $2.81B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.0% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were KRYS ($379.02M), PODD ($225.26M), NVCR ($150.34M). By sector, the heaviest allocations are Health Care 98.6%, Technology 0.0%.

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 56% of names.

The largest new positions opened in Q3 2026 were ZLAB ($40.64M), KOD ($27.20M), INBX ($21.02M).

Of the 27 positions fully exited versus the prior quarter, the largest were GMED ($37.05M), SUPN ($24.19M), LIVN ($20.97M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ZLAB ZAI LAB LTD · $40.64M
  • KOD KODIAK SCIENCES INC · $27.20M
  • INBX INHIBRX BIOSCIENCES INC · $21.02M
  • CNMD CONMED CORP · $16.06M
  • ETON ETON PHARMACEUTICALS INC · $15.86M
  • GRAL GRAIL INC · $15.20M
  • AMRX AMNEAL PHARMACEUTICALS INC · $13.25M
  • SNY SANOFI SA · $11.34M

Fully Exited (vs previous quarter)

  • GMED GLOBUS MED INC · prev qtr: $37.05M
  • SUPN SUPERNUS PHARMACEUTICALS · prev qtr: $24.19M
  • LIVN LIVANOVA PLC · prev qtr: $20.97M
  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $13.05M
  • ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $9.95M
  • IMVT IMMUNOVANT INC · prev qtr: $9.71M
  • NKTR NEKTAR THERAPEUTICS · prev qtr: $8.96M
  • MIRM MIRUM PHARMACEUTICALS INC · prev qtr: $8.78M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to biotech/healthcare names (e.g., KRYS, PODD, UTHR, ERAS) while trimming others (e.g., NVCR, TGTX, CELC), suggesting a bullish but selective stance on healthcare innovation, particularly in gene therapy and diabetes management. 2. Key moves: - Added: KRYS (+21.3% shares), PODD (+64.6% shares), UTHR (+14.8% shares), ERAS (+89.3% shares). - Reduced: NVCR (-4.9% shares), TGTX (-12.7% shares), CELC (-1.3% shares), INSP (-37.5% shares), BBNX (-14.8% shares). 3. Portfolio structure: Active, concentrated (97 positions), heavily biased toward Health Care (100% of top 10), with high risk appetite (volatile biotech names, significant share swings). 4. Per-holding one-liner: - KRYS: Krystal Biotech (gene therapy) - PODD: Insulet (insulin pumps) - NVCR: Novocure (tumor treatment fields) - TGTX: TG Therapeutics (B-cell malignancies) - UTHR: United Therapeutics (pulmonary hypertension) - CELC: Celcuity (cancer diagnostics) - RIGL: Rigel Pharmaceuticals (autoimmune/inflammatory) - INSP: Inspire Med Systems (sleep apnea) - ERAS: Erasca (cancer therapeutics) - BBNX: Beta Bionics (artificial pancreas) 5. Style summary: Aggressive biotech focus with tactical bets on high-growth therapeutics and devices, trimming laggards.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:03

Sector Allocation

Health Care 98.6%
Technology 0.0%
Other 1.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.14M $379.02M 13.47%
13.47%
Add
2 1.73M $225.26M 8.01%
8.01%
Add
3 9.43M $150.34M 5.34%
5.34%
Reduce
4 2.56M $142.58M 5.07%
5.07%
Reduce
5 259.00K $140.35M 4.99%
4.99%
Add
6 1.68M $133.81M 4.76%
4.76%
Reduce
7 1.84M $88.76M 3.15%
3.15%
Hold
8 1.21M $83.71M 2.98%
2.98%
Reduce
9 5.11M $74.94M 2.66%
2.66%
Add
10 3.74M $71.06M 2.53%
2.53%
Reduce
11 975.50K $70.87M 2.52%
2.52%
Add
12 1.55M $62.38M 2.22%
2.22%
Add
13 46.77M $57.53M 2.04%
2.04%
Add
14 1.68M $54.39M 1.93%
1.93%
Add
15 49.35K $47.32M 1.68%
1.68%
Add
16 1.08M $45.32M 1.61%
1.61%
Add
17 3.22M $44.28M 1.57%
1.57%
Add
18 5.09M $40.72M 1.45%
1.45%
Add
19 1.54M $40.64M 1.45%
1.45%
New
20 1.58M $39.85M 1.42%
1.42%
Reduce
21 2.73M $39.06M 1.39%
1.39%
Add
22 1.71M $36.13M 1.28%
1.28%
Add
23 7.31M $32.67M 1.16%
1.16%
Hold
24 1.02M $29.03M 1.03%
1.03%
Add
25 286.97K $27.20M 0.97%
0.97%
New
26 2.39M $26.08M 0.93%
0.93%
Add
27 11.22M $23.07M 0.82%
0.82%
Add
28 862.00K $22.27M 0.79%
0.79%
Reduce
29 1.09M $21.59M 0.77%
0.77%
Reduce
30 892.16K $21.15M 0.75%
0.75%
Reduce
31 210.00K $21.02M 0.75%
0.75%
New
32 1.27M $20.36M 0.72%
0.72%
Add
33 15.00M $20.24M 0.72%
0.72%
Add
34 497.71K $20.17M 0.72%
0.72%
Reduce
35 802.30K $20.02M 0.71%
0.71%
Add
36 667.84K $19.92M 0.71%
0.71%
Add
37 604.00K $19.16M 0.68%
0.68%
Reduce
38 147.00K $16.78M 0.60%
0.60%
Add
39 56.52K $16.46M 0.58%
0.58%
Reduce
40 1.17M $16.45M 0.58%
0.58%
Reduce
41 218.96K $16.34M 0.58%
0.58%
Reduce
42 347.33K $16.06M 0.57%
0.57%
New
43 308.10K $15.86M 0.56%
0.56%
New
44 710.20K $15.82M 0.56%
0.56%
Reduce
45 11.30M $15.48M 0.55%
0.55%
Add
46 108.50K $15.20M 0.54%
0.54%
New
47 258.90K $15.18M 0.54%
0.54%
Reduce
48 329.99K $13.40M 0.48%
0.48%
Reduce
49 658.00K $13.25M 0.47%
0.47%
New
50 3.38M $13.21M 0.47%
0.47%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Low-confidence forecast This fund replaces about 37% of its Top-10 each quarter and backtests at F1 62% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 62% · recall 62% · F1 62% · avg rank error 2.8 · Top-10 turnover 37%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 50% 50% 50% TEVA · UTHR · RYZB · GSK · FOCL · ORGO · HUM · CELC · IRMD · EPIX XBI · UTHR · FOCL · IOVA · TEVA · TGTX · CELC · JSPR · NPCE · EPIX
2024-Q2 50% 50% 50% XBI · UTHR · IOVA · TGTX · FOCL · TEVA · CELC · NPCE · JSPR · EPIX TGTX · IOVA · UTHR · NRIX · FOCL · TERN · RVMD · SRDX · ORGO · JSPR
2024-Q3 50% 50% 50% TGTX · IOVA · NRIX · UTHR · FOCL · RVMD · TERN · ORGO · SRDX · KRYS XBI · IOVA · TGTX · TERN · AXGN · GRFS · KRYS · CCCC · UTHR · SNY
2024-Q4 70% 70% 70% IOVA · XBI · TGTX · TERN · KRYS · CCCC · AXGN · GRFS · SNY · IDYA XBI · NVCR · TGTX · BMRN · KRYS · GRFS · AXGN · IOVA · TEVA · TERN
2025-Q1 60% 60% 60% XBI · NVCR · TGTX · BMRN · KRYS · GRFS · TEVA · AXGN · IOVA · TERN XBI · TGTX · NVCR · KRYS · BMRN · ORGO · GRFS · UTHR · STAA · PRAX
2025-Q2 90% 90% 90% XBI · TGTX · NVCR · KRYS · BMRN · ORGO · GRFS · UTHR · PRAX · STAA KRYS · NVCR · TGTX · XBI · UTHR · BBNX · GRFS · STAA · BMRN · ORGO
2025-Q3 60% 60% 60% KRYS · NVCR · TGTX · UTHR · BBNX · XBI · STAA · GRFS · BMRN · PRAX KRYS · TGTX · NVCR · XBI · ELV · BBNX · UTHR · TERN · CELC · INSP
2025-Q4 50% 50% 50% KRYS · TGTX · NVCR · XBI · ELV · BBNX · UTHR · INSP · TERN · TWST XBI · KRYS · CELC · NVCR · PRAX · TGTX · DXCM · BMRN · GMED · BBNX
2026-Q1 50% 50% 50% XBI · KRYS · CELC · NVCR · TGTX · PRAX · GMED · DXCM · FOLD · BMRN KRYS · CELC · TGTX · PODD · NVCR · UTHR · PRAX · VCEL · ALKS · ANIP
2026-Q2 60% 60% 60% KRYS · CELC · TGTX · PODD · UTHR · NVCR · PRAX · VCEL · ALKS · GMED KRYS · CELC · TGTX · PODD · NVCR · UTHR · INSP · RIGL · ANIP · BBNX
2026-Q3 ★ 90% 90% 90% KRYS · PODD · CELC · TGTX · NVCR · UTHR · INSP · RIGL · ANIP · BBNX KRYS · PODD · NVCR · TGTX · UTHR · CELC · RIGL · INSP · ERAS · BBNX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings11 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return+0.30%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+17.31%vs benchmark
Barra annualised vol32.7%Model estimate
Realised vol34.4%Annualised in window
Weighted beta0.61Raw exposure
Factor / specific risk55% / 45%Share of variance
Top-10 concentration99.9%Of reported value
Portfolio value (start = 100)78.185.793.3100.8108.410-0110-2311-16Soleus Capital Management, L.P.QQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+0.30%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+17.31%Portfolio − benchmark
Arithmetic return sum+1.06%Difference vs compounded is the cross term
Weighted raw beta0.61Weighted holding betas
Realised volatility (annualised)34.44%Daily returns in window
Barra model volatility (annualised)32.75%Factor + specific
Factor share of variance55.2%Barra factors
Specific share of variance44.8%Stock residuals
Reported value$287.8M13F long US equity

2. Return attribution

The +1.06% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +4.24% 399.5%
Momentum & Growth 3 -1.94% -182.9%
Volatility & Tail Risk 7 +2.95% 277.5%
Industry 12 +6.98% 657.5%
Specific 1 -11.17% -1051.6%
Return attribution (style + industry, %)-15.6-7.8+0.0+7.8+15.6Amihud Illiquidity-0.43Short-term Reversal-0.51Mid Cap-1.12Beta-1.16Leverage (Downside Vol)+1.23Non-linear Size+1.34Momentum-1.61Turnover+1.80Size+2.29Residual Volatility+3.59Historical Volatility-6.12Health Care+6.98Skewness-8.58Kurtosis+14.41
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +1.92 +7.51% +14.41% 1356.7%
Health Care Industry +1.00 +6.98% +6.98% 657.5%
Residual Volatility Style +1.09 +3.29% +3.59% 337.9%
Size Style -1.17 -1.95% +2.29% 215.2%
Turnover Style -0.37 -4.80% +1.80% 169.3%
Non-linear Size Style +1.33 +1.01% +1.34% 126.6%
Leverage (Downside Vol) Style -0.72 -1.71% +1.23% 115.7%
Liquidity Style +1.04 +0.36% +0.37% 35.0%
Growth Style +0.10 +1.75% +0.18% 17.1%
Max Drawdown Style +0.24 -1.76% -0.42% -39.3%
Amihud Illiquidity Style +0.97 -0.45% -0.43% -40.8%
Short-term Reversal Style -0.59 +0.87% -0.51% -48.3%
Mid Cap Style +0.58 -1.94% -1.12% -105.9%
Beta Style -0.26 +4.44% -1.16% -109.2%
Momentum Style +0.40 -4.00% -1.61% -151.8%
Historical Volatility Style +0.44 -14.00% -6.12% -576.3%
Skewness Style +1.95 -4.39% -8.58% -808.0%
Specific Specific — — -11.17% -1051.6%

3. Risk attribution

Annualised volatility is 32.75%; factor risk explains 55.2% of variance and specific risk 44.8%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-48.3-24.2+0.0+24.2+48.3Leverage (Downside Vol)-3.34Max Drawdown-0.96Mid Cap+1.20Momentum+1.35Historical Volatility+1.45Non-linear Size+1.61Residual Volatility+2.28Size+3.17Short-term Reversal+3.67Liquidity+4.04Kurtosis+5.31Skewness+14.83Health Care+21.07Specific+44.76
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 44.8% +14.66% 14.7%
Health Care Industry +1.00 21.1% +6.90% 6.9%
Skewness Style +1.95 14.8% +4.86% 4.9%
Kurtosis Style +1.92 5.3% +1.74% 1.7%
Liquidity Style +1.04 4.0% +1.32% 1.3%
Short-term Reversal Style -0.59 3.7% +1.20% 1.2%
Size Style -1.17 3.2% +1.04% 1.0%
Residual Volatility Style +1.09 2.3% +0.75% 0.8%
Non-linear Size Style +1.33 1.6% +0.53% 0.5%
Historical Volatility Style +0.44 1.4% +0.47% 0.5%
Momentum Style +0.40 1.4% +0.44% 0.4%
Mid Cap Style +0.58 1.2% +0.39% 0.4%
Turnover Style -0.37 0.3% +0.10% 0.1%
Growth Style +0.10 -0.7% -0.22% -0.2%
Max Drawdown Style +0.24 -1.0% -0.31% -0.3%
Leverage (Downside Vol) Style -0.72 -3.3% -1.09% -1.1%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.5-0.50.51.42.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.17 +2.10 -3.27
Non-linear Size +1.33 +1.68 -0.34
Mid Cap +0.58 +0.13 +0.45
Beta -0.26 +1.29 -1.56
Momentum +0.40 +0.72 -0.31
Short-term Reversal -0.59 -0.64 +0.06
Residual Volatility +1.09 -0.40 +1.49
Historical Volatility +0.44 +0.86 -0.42
Liquidity +1.04 +0.11 +0.93
Amihud Illiquidity +0.97 +1.16 -0.18
Turnover -0.38 +0.21 -0.58
Growth +0.10 +0.58 -0.48
Leverage (Downside Vol) -0.72 +0.14 -0.86
Skewness +1.95 +0.24 +1.72
Kurtosis +1.92 +0.21 +1.70
Max Drawdown +0.24 -0.08 +0.32

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Health Care 100.0% 1.7% -0.05% +8.29% +24.98% -0.14% -8.20% -0.20%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Total +23.98% +15.70% -24.04% +15.64%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
UTHR UNITED THERAPEUTICS CORP DEL Health Care 48.77% +8.49% +4.14% Add
ARGX ARGENX SE Health Care 16.44% -0.83% -0.14% Add
LEGN LEGEND BIOTECH CORP Health Care 7.50% -19.61% -1.47% Reduce
TNGX TANGO THERAPEUTICS INC Health Care 6.96% -3.13% -0.22% Add
INSM INSMED INC Health Care 5.83% +7.66% +0.45% Add
GRAL GRAIL INC Health Care 5.28% -24.64% -1.30% New
TWST TWIST BIOSCIENCE CORP Health Care 3.19% -45.64% -1.46% Reduce
AZN ASTRAZENECA PLC Health Care 2.95% +13.96% +0.41% New
RVMD REVOLUTION MEDICINES INC Health Care 2.58% -18.70% -0.48% New
MNKD MANNKIND CORP Health Care 0.41% +1.41% +0.01% New
UNH UNITEDHEALTH GROUP INC Health Care 0.08% +12.24% +0.01% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 UTHR Health Care 48.77% +8.49% +4.14%
2 INSM Health Care 5.83% +7.66% +0.45%
3 AZN Health Care 2.95% +13.96% +0.41%
4 UNH Health Care 0.08% +12.24% +0.01%
5 MNKD Health Care 0.41% +1.41% +0.01%
6 ARGX Health Care 16.44% -0.83% -0.14%
7 TNGX Health Care 6.96% -3.13% -0.22%
8 RVMD Health Care 2.58% -18.70% -0.48%
9 GRAL Health Care 5.28% -24.64% -1.30%
10 TWST Health Care 3.19% -45.64% -1.46%
11 LEGN Health Care 7.50% -19.61% -1.47%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +0.30%, versus -17.01% for the QQQ synthetic benchmark — an excess of +17.31%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +14.41%, Health Care +6.98%, Residual Volatility +3.59%; the largest drags came from Skewness -8.58%, Historical Volatility -6.12%, Momentum -1.61%. Specific (stock-level) return contributed -11.17%.
  3. Risk attribution: Barra model volatility is 32.75% annualised; factor risk explains 55% of variance and specific risk 45%. The largest factor risk sources are Health Care 21.1%, Skewness 14.8%, Kurtosis 5.3%.
  4. Style tilt: size -1.17, momentum +0.40, volatility +0.44, liquidity +1.04; the weighted raw beta is 0.61. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.70% and interaction -24.04%.
  6. Concentration: the top-10 positions are 99.9% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Soleus Capital Management, L.P. buy in 2026-Q3?

In its 2026-Q3 13F filing, Soleus Capital Management, L.P. reported 97 equity positions worth $2.81B in aggregate; its largest disclosed positions were KRYS ($379.02M), PODD ($225.26M), NVCR ($150.34M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $2.81B of long equity holdings across 97 positions as of 2026-Q3. Top-10 holdings account for 53.0% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →